Michael Hogarty
Overview
Explore the profile of Michael Hogarty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weagley J, Makimaa H, Cardenas L, Romani A, Sullender M, Aggarwal S, et al.
bioRxiv
. 2025 Jan;
PMID: 39868290
Mouse models are vital tools for discerning the relative contributions of host and microbial genetics to disease, often requiring the transplantation of microbiota between different mouse strains. Transfer methods include...
2.
Bielamowicz K, Dimitrion P, Abla O, Bomken S, Campbell P, Collin M, et al.
Cancer
. 2024 Apr;
130(14):2416-2439.
PMID: 38687639
Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder characterized by lesions with CD1a-positive/Langerin (CD207)-positive histiocytes and inflammatory infiltrate that can cause local tissue damage and systemic inflammation. Clinical presentations...
3.
Moreno L, Guo D, Irwin M, Berthold F, Hogarty M, Kamijo T, et al.
Pediatr Blood Cancer
. 2020 Nov;
68(3):e28794.
PMID: 33205902
Background: Long-term outcome remains poor for children with high-risk neuroblastoma (five-year overall survival [OS] ∼50%). Our objectives were to (a) identify prognostic biomarkers and apply them in a nomogram to...
4.
Sokol E, Desai A, Applebaum M, Valteau-Couanet D, Park J, Pearson A, et al.
J Clin Oncol
. 2020 Sep;
38(31):3720-3721.
PMID: 32931402
No abstract available.
5.
Campbell K, Naranjo A, Hibbitts E, Gastier-Foster J, Bagatell R, Irwin M, et al.
Eur J Cancer
. 2020 Jun;
133:112-119.
PMID: 32492633
Purpose: MYCN amplification (MNA) is associated with poor outcomes in neuroblastoma. Less is known about heterogeneous MNA within a tumour. We compared clinical characteristics, biologic features and clinical outcomes of...
6.
Sokol E, Desai A, Applebaum M, Valteau-Couanet D, Park J, Pearson A, et al.
J Clin Oncol
. 2020 Apr;
38(17):1906-1918.
PMID: 32315273
Purpose: The Children's Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked...
7.
Temple W, Mendelsohn L, Kim G, Nekritz E, Gustafson W, Lin L, et al.
Eur J Nucl Med Mol Imaging
. 2016 Apr;
43(7):1396.
PMID: 27044383
No abstract available.
8.
Temple W, Mendelsohn L, Kim G, Nekritz E, Gustafson W, Lin L, et al.
Eur J Nucl Med Mol Imaging
. 2015 Sep;
43(3):474-481.
PMID: 26338179
Purpose: Vesicular monoamine transporters 1 and 2 (VMAT1 and VMAT2) are thought to mediate MIBG uptake in adult neuroendocrine tumors. In neuroblastoma, the norepinephrine transporter (NET) has been investigated as...
9.
Park J, Bagatell R, London W, Maris J, Cohn S, Mattay K, et al.
Pediatr Blood Cancer
. 2012 Dec;
60(6):985-93.
PMID: 23255319
Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For...
10.
Miller M, Ohashi K, Zhu X, McGrady P, London W, Hogarty M, et al.
J Pediatr Hematol Oncol
. 2006 Jul;
28(7):412-7.
PMID: 16825985
Alterations in apoptotic mechanisms favoring cell survival may be vital for modifying tumor behavior. Survivin, an inhibitor of apoptosis, and caspase 8, a proapoptotic enzyme, are key players in cellular...